These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19706084)

  • 1. A novel gel formulation of 0.25% tretinoin and 1.2% clindamycin phosphate: efficacy in acne vulgaris patients aged 12 to 18 years.
    Eichenfield LF; Wortzman M
    Pediatr Dermatol; 2009; 26(3):257-61. PubMed ID: 19706084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clindamycin phosphate 1.2% / tretinoin 0.025%: a novel fixed-dose combination treatment for acne vulgaris.
    Ochsendorf F
    J Eur Acad Dermatol Venereol; 2015 Jun; 29 Suppl 5():8-13. PubMed ID: 26059820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel gel formulation of clindamycin phosphate-tretinoin is not associated with acne flaring.
    Leyden JJ; Wortzman M
    Cutis; 2008 Aug; 82(2):151-6. PubMed ID: 18792548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
    Tanghetti E; Dhawan S; Torok H; Kircik L
    Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies.
    Dréno B; Bettoli V; Ochsendorf F; Layton AM; Perez M; Dakovic R; Gollnick H
    Eur J Dermatol; 2014; 24(2):201-9. PubMed ID: 24704684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study.
    Jarratt MT; Brundage T
    J Drugs Dermatol; 2012 Mar; 11(3):318-26. PubMed ID: 22395582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel in acne vulgaris.
    Cambazard F
    J Eur Acad Dermatol Venereol; 1998 Sep; 11 Suppl 1():S20-7; discussion S28-9. PubMed ID: 9891905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris.
    Schlessinger J; Menter A; Gold M; Leonardi C; Eichenfield L; Plott RT; Leyden J; Wortzman M;
    J Drugs Dermatol; 2007 Jun; 6(6):607-15. PubMed ID: 17668526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study.
    Kircik LH; Peredo MI; Bucko AD; Loss RW; Fowler JF; Wortzman M; Neumaier GJ
    Cutis; 2008 Nov; 82(5):358-66. PubMed ID: 19090341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne.
    Richter JR; Förström LR; Kiistala UO; Jung EG
    J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):227-33. PubMed ID: 9883434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study.
    Bowman S; Gold M; Nasir A; Vamvakias G
    J Drugs Dermatol; 2005; 4(5):611-8. PubMed ID: 16167420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized tolerability analysis of clindamycin phosphate 1.2%-tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris.
    Draelos ZD; Potts A; Alió Saenz AB;
    Cutis; 2010 Dec; 86(6):310-8. PubMed ID: 21284283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations.
    Webster G; Rich P; Gold MH; Mraz S; Calvarese B; Chen D
    J Drugs Dermatol; 2009 Aug; 8(8):736-43. PubMed ID: 19663111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel.
    Leyden J; Wortzman M; Baldwin EK
    J Drugs Dermatol; 2009 Apr; 8(4):383-8. PubMed ID: 19363857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
    Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
    Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational Study of Clindamycin Phosphate and Tretinoin Gel for the Treatment of Acne.
    Ohlson J; Dakovic R; Berg M
    J Drugs Dermatol; 2019 Apr; 18(4):328-334. PubMed ID: 31012560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability.
    Del Rosso JQ; Jitpraphai W; Bhambri S; Momin S
    Cutis; 2008 May; 81(5):405-8. PubMed ID: 18543590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris.
    Pazoki-Toroudi H; Nilforoushzadeh MA; Ajami M; Jaffary F; Aboutaleb N; Nassiri-Kashani M; Firooz A
    Cutan Ocul Toxicol; 2011 Dec; 30(4):286-91. PubMed ID: 21612319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
    Eichenfield LF; Alió Sáenz AB
    J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris.
    Zaenglein AL; Shamban A; Webster G; Del Rosso J; Dover JS; Swinyer L; Stein L; Lin X; Draelos Z; Gold M; Thiboutot D
    J Drugs Dermatol; 2013 Jun; 12(6):619-25. PubMed ID: 23839176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.